Zip6-attenuation promotes epithelial-to-mesenchymal transition in ductal breast tumor (T47D) cells

Veronica Lopez, Shannon L. Kelleher

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

Breast cancer is associated with zinc (Zn) hyper-accumulation in breast tissue which is postulated to be potentiated by the over-expression of Zn importing proteins. Zip6 (LIV-1) over-expression has been documented in estrogen receptor-positive (ER+) breast tumors. Anti-estrogens, such as fulvestrant, are typically prescribed for ER+ breast cancer and thus may play a role in modulating cellular Zn hyper-accumulation. Herein, we investigated the physiological relevance of Zip6 over-expression and the consequences of Zip6-attenuation in breast tumor cells as a mechanism in the development of anti-estrogen resistance. We documented that over-expression of Zip6 was associated with significantly higher cellular Zn levels in tumor cells compared with normal breast cells. Fulvestrant significantly reduced Zn accumulation in tumor cells, without robust effects on Zip6 protein abundance. Zip6-attenuation significantly reduced cellular Zn pools, which was associated with increased mitochondrial membrane potential (ΔΨm) and decreased apoptotic stimuli (cytoplasmic cytochrome C release, caspase- 3 and - 9 activities). Importantly, decreased apoptosis significantly increased tumor colony formation in soft agar and was associated with reduced E-cadherin expression. Our data suggest that anti-estrogen treatment regulates Zn level and importantly verify that Zip6 over-expression is not an underlying mechanism initiating breast cancer, but in fact may play a "tumor-constraining" role.

Original languageEnglish (US)
Pages (from-to)366-375
Number of pages10
JournalExperimental Cell Research
Volume316
Issue number3
DOIs
StatePublished - Feb 1 2010

Fingerprint

Epithelial-Mesenchymal Transition
Zinc
Breast Neoplasms
Estrogens
Neoplasms
Breast
Caspase 9
Mitochondrial Membrane Potential
Cadherins
Cytochromes
Caspase 3
Estrogen Receptors
Agar
Proteins
Apoptosis

All Science Journal Classification (ASJC) codes

  • Cell Biology

Cite this

Lopez, Veronica ; Kelleher, Shannon L. / Zip6-attenuation promotes epithelial-to-mesenchymal transition in ductal breast tumor (T47D) cells. In: Experimental Cell Research. 2010 ; Vol. 316, No. 3. pp. 366-375.
@article{d84210bc5ddc4df7957de9933ba62266,
title = "Zip6-attenuation promotes epithelial-to-mesenchymal transition in ductal breast tumor (T47D) cells",
abstract = "Breast cancer is associated with zinc (Zn) hyper-accumulation in breast tissue which is postulated to be potentiated by the over-expression of Zn importing proteins. Zip6 (LIV-1) over-expression has been documented in estrogen receptor-positive (ER+) breast tumors. Anti-estrogens, such as fulvestrant, are typically prescribed for ER+ breast cancer and thus may play a role in modulating cellular Zn hyper-accumulation. Herein, we investigated the physiological relevance of Zip6 over-expression and the consequences of Zip6-attenuation in breast tumor cells as a mechanism in the development of anti-estrogen resistance. We documented that over-expression of Zip6 was associated with significantly higher cellular Zn levels in tumor cells compared with normal breast cells. Fulvestrant significantly reduced Zn accumulation in tumor cells, without robust effects on Zip6 protein abundance. Zip6-attenuation significantly reduced cellular Zn pools, which was associated with increased mitochondrial membrane potential (ΔΨm) and decreased apoptotic stimuli (cytoplasmic cytochrome C release, caspase- 3 and - 9 activities). Importantly, decreased apoptosis significantly increased tumor colony formation in soft agar and was associated with reduced E-cadherin expression. Our data suggest that anti-estrogen treatment regulates Zn level and importantly verify that Zip6 over-expression is not an underlying mechanism initiating breast cancer, but in fact may play a {"}tumor-constraining{"} role.",
author = "Veronica Lopez and Kelleher, {Shannon L.}",
year = "2010",
month = "2",
day = "1",
doi = "10.1016/j.yexcr.2009.10.011",
language = "English (US)",
volume = "316",
pages = "366--375",
journal = "Experimental Cell Research",
issn = "0014-4827",
publisher = "Academic Press Inc.",
number = "3",

}

Zip6-attenuation promotes epithelial-to-mesenchymal transition in ductal breast tumor (T47D) cells. / Lopez, Veronica; Kelleher, Shannon L.

In: Experimental Cell Research, Vol. 316, No. 3, 01.02.2010, p. 366-375.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Zip6-attenuation promotes epithelial-to-mesenchymal transition in ductal breast tumor (T47D) cells

AU - Lopez, Veronica

AU - Kelleher, Shannon L.

PY - 2010/2/1

Y1 - 2010/2/1

N2 - Breast cancer is associated with zinc (Zn) hyper-accumulation in breast tissue which is postulated to be potentiated by the over-expression of Zn importing proteins. Zip6 (LIV-1) over-expression has been documented in estrogen receptor-positive (ER+) breast tumors. Anti-estrogens, such as fulvestrant, are typically prescribed for ER+ breast cancer and thus may play a role in modulating cellular Zn hyper-accumulation. Herein, we investigated the physiological relevance of Zip6 over-expression and the consequences of Zip6-attenuation in breast tumor cells as a mechanism in the development of anti-estrogen resistance. We documented that over-expression of Zip6 was associated with significantly higher cellular Zn levels in tumor cells compared with normal breast cells. Fulvestrant significantly reduced Zn accumulation in tumor cells, without robust effects on Zip6 protein abundance. Zip6-attenuation significantly reduced cellular Zn pools, which was associated with increased mitochondrial membrane potential (ΔΨm) and decreased apoptotic stimuli (cytoplasmic cytochrome C release, caspase- 3 and - 9 activities). Importantly, decreased apoptosis significantly increased tumor colony formation in soft agar and was associated with reduced E-cadherin expression. Our data suggest that anti-estrogen treatment regulates Zn level and importantly verify that Zip6 over-expression is not an underlying mechanism initiating breast cancer, but in fact may play a "tumor-constraining" role.

AB - Breast cancer is associated with zinc (Zn) hyper-accumulation in breast tissue which is postulated to be potentiated by the over-expression of Zn importing proteins. Zip6 (LIV-1) over-expression has been documented in estrogen receptor-positive (ER+) breast tumors. Anti-estrogens, such as fulvestrant, are typically prescribed for ER+ breast cancer and thus may play a role in modulating cellular Zn hyper-accumulation. Herein, we investigated the physiological relevance of Zip6 over-expression and the consequences of Zip6-attenuation in breast tumor cells as a mechanism in the development of anti-estrogen resistance. We documented that over-expression of Zip6 was associated with significantly higher cellular Zn levels in tumor cells compared with normal breast cells. Fulvestrant significantly reduced Zn accumulation in tumor cells, without robust effects on Zip6 protein abundance. Zip6-attenuation significantly reduced cellular Zn pools, which was associated with increased mitochondrial membrane potential (ΔΨm) and decreased apoptotic stimuli (cytoplasmic cytochrome C release, caspase- 3 and - 9 activities). Importantly, decreased apoptosis significantly increased tumor colony formation in soft agar and was associated with reduced E-cadherin expression. Our data suggest that anti-estrogen treatment regulates Zn level and importantly verify that Zip6 over-expression is not an underlying mechanism initiating breast cancer, but in fact may play a "tumor-constraining" role.

UR - http://www.scopus.com/inward/record.url?scp=72149086674&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=72149086674&partnerID=8YFLogxK

U2 - 10.1016/j.yexcr.2009.10.011

DO - 10.1016/j.yexcr.2009.10.011

M3 - Article

C2 - 19852955

AN - SCOPUS:72149086674

VL - 316

SP - 366

EP - 375

JO - Experimental Cell Research

JF - Experimental Cell Research

SN - 0014-4827

IS - 3

ER -